**Name of Journal:** *World Journal of Gastroenterology*

**Manuscript NO:** 74622

**Manuscript Type:** ORIGINAL ARTICLE

***Basic Study***

**Peroxisome proliferator-activated receptor-alpha activation and dipeptidyl peptidase-4 inhibition target dysbiosis to treat fatty liver in obese mice**

Silva-Veiga FM *et al*. Dysbiosis and NAFLD treatment in HF-fed mice

Flavia Maria Silva-Veiga, Carolline Santos Miranda, Isabela Macedo Lopes Vasques-Monteiro, Henrique Souza-Tavares, Fabiane Ferreira Martins, Julio Beltrame Daleprane, Vanessa Souza-Mello

**Flavia Maria Silva-Veiga, Carolline Santos Miranda, Isabela Macedo Lopes Vasques-Monteiro, Henrique Souza-Tavares, Fabiane Ferreira Martins, Vanessa Souza-Mello,** Department of Anatomy, Institute of Biology, State University of Rio de Janeiro, Laboratory of Morphometry, Metabolism and Cardiovascular Diseases, Rio de Janeiro 20551-030, Brazil

**Julio Beltrame Daleprane,** Department of Clinical and Toxicology Analysis, State University of Rio de Janeiro, Nutrition Institute, State University of Rio de Janeiro, Nutrition Institute, University of Sao Paulo, Rio de Janeiro 20551-030, Brazil

**Author contributions:** Silva-Veiga FM, Martins FF, Daleprane JB, and Souza-Mello V designed and coordinated the study; Silva-Veiga FM, Miranda CS, Vasques-Monteiro IML, Souza-Tavares H, Martins FF, Daleprane JB, and Souza-Mello V performed the experiments, acquired and analyzed data; Silva-Veiga FM, Miranda CS, Vasques-Monteiro IML, Martins FF, Daleprane JB, and Souza-Mello V interpreted the data; Silva-Veiga FM and Souza-Mello V wrote the manuscript; all authors approved the final version of the article.

**Supported by** Coordenação de Aperfeiçoamento de Pessoal de Nível Superior–Brasil, No. CAPES–Finance Code 001; Fundação Carlos Chagas Filho de Amparo à Pesquisa do Rio de Janeiro (FAPERJ) to Souza-Mello V, No. E-26/202.657/2018 and No. E-26/010.002136/2019; The corresponding author is supported by Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq), No. 303785/2020-9.

**Corresponding author: Vanessa Souza-Mello, PhD, Associate Professor,** Department of Anatomy, Institute of Biology, State University of Rio de Janeiro, Laboratory of Morphometry, Metabolism and Cardiovascular Diseases, Blvd. 28 de Setembro 87, Fundos, Vila Isabel, Rio de Janeiro 20551-030, Brazil. souzamello.uerj@gmail.com

**Received:** December 30, 2021

**Revised:** February 4, 2022

**Accepted: March 26, 2022**

**Published online:**

**Abstract**

BACKGROUND

Obesity and comorbidities onset encompass gut dysbiosis, altered intestinal permeability, and endotoxemia. Treatments that target gut dysbiosis can cope with obesity and nonalcoholic fatty liver disease (NAFLD) management. Peroxisome proliferator-activated receptor (PPAR)-alpha activation and dipeptidyl-peptidase-4 (DPP-4) inhibition alleviate NAFLD, but the mechanism may involve gut microbiota modulation and merits further investigation.

AIM

To address the effects of PPAR-alpha activation and DPP-4 inhibition (isolated or combined) upon the gut-liver axis, emphasizing inflammatory pathways in NAFLD management in high-fat-fed C57BL/6J mice.

METHODS

Male C57BL/6J mice were fed a control diet (C, 10% of energy as lipids) or a high-fat diet (HFD, 50% of energy as lipids) for 12 wk, when treatments started, forming the groups: C, HF, HFA (HFD + PPAR-alpha agonist WY14643, 2.5 mg/kg body mass), HFL (HFD + DPP-4 inhibitor linagliptin, 15 mg/kg body mass), and HFC (HFD + the combination of WY14643 and linagliptin).

RESULTS

The HFD was obesogenic compared to the C diet. All treatments elicited significant body mass loss, and the HFC group showed similar body mass to the C group. All treatments tackled oral glucose intolerance and raised plasma glucagon-like peptide-1 concentrations. These metabolic benefits restored *Bacteroidetes*/*Firmicutes* ratio, resulting in increased goblet cells *per* area of the large intestine and reduced lipopolysaccharides concentrations in treated groups. At the gene level, treated groups showed higher intestinal *Mucin 2*, *Occludin*, and *Zo-1* expression than the HFD group. The reduced endotoxemia suppressed inflammasome and macrophage gene expression in the liver of treated animals. These observations complied with the mitigation of liver steatosis and reduced hepatic triacylglycerol, reassuring the role of the proposed treatments on NAFLD mitigation.

CONCLUSION

PPAR alpha activation and DPP-4 inhibition (isolated or combined) tackled NAFLD in diet-induced obese mice by restoration of gut-liver axis. The reestablishment of the intestinal barrier and the rescued phylogenetic gut bacteria distribution mitigated liver steatosis through anti-inflammatory signals. These results can cope with NAFLD management by providing pre-clinical evidence that drugs used to treat obesity comorbidities can help to alleviate this silent and harmful liver disease.

**Key Words:** Nonalcoholic fatty liver disease; High-fat diet; Peroxisome proliferator-activated receptor-alpha; Dipeptidyl-peptidase-4-inhibitor; Dysbiosis; Inflammation

Silva-Veiga FM, Miranda CS, Vasques-Monteiro IML, Souza-Tavares H, Martins FF, Daleprane JB, Souza-Mello V. Peroxisome proliferator-activated receptor-alpha activation and dipeptidyl peptidase-4 inhibition target dysbiosis to treat fatty liver in obese mice. *World J Gastroenterol* 2022; In press

**Core Tip:** Chronic high-fat diet (HF) intake alters the phylogenetic microbiota composition, sending harmful proinflammatory signals to the liver that elicit nonalcoholic fatty liver disease (NAFLD) in mice. Here, we treated HF diet-induced obese mice with a peroxisome proliferator-activated receptor-alpha agonist (WY14643), a dipeptidyl-peptidase-4 inhibitor (linagliptin), or their combination, focusing on gut–liver axis modulation. The treatments rescued gut dysbiosis and endotoxemia due to increased tight junction gene expression, mucin production, and numerical density of goblet cells in the intestinal crypts. Treated mice benefited from downregulated *Tlr4*, *Cd206*, and *Nlrp3*, alleviating fatty liver through anti-inflammatory signals such as increased *IL-10* and *IL-13*.

**INTRODUCTION**

The prevalence of obesity worldwide has tripled during recent decades, necessitating large budgets for public health systems due to associated comorbidities[1,2]. Excessive dietary saturated fat intake triggers insulin resistance, white adipocyte hypertrophy, low-grade inflammation (metainflammation), brown adipose tissue dysfunction (whitening), fatty liver, and, as more recently described, alteration in the composition of the gut microbiota (dysbiosis)[3,4].

The digestive tract is populated by several microorganisms, predominantly including bacteria from the *Firmicutes* and *Bacteroidetes* phyla, and this population is influenced by the quality of the diet[5]. Excessive saturated fat in the diet increases the proportion of gram-negative bacteria with lipopolysaccharides (LPS) in the composition of their outer wall[6]. LPS is an endotoxin that compromises the integrity of the intestinal mucosa through alterations in the structural proteins of tight junctions (TJs), resulting in increased intestinal permeability and the migration of LPS to other tissues[5,7].

The gut–liver axis comprises the anatomical communication between these two organs *via* the portal vein[8]. A recent study by our group has demonstrated phylogenetic changes in the gut microbiota of mice after seventeen weeks of high-fructose diet feeding, with a significant increase in liver steatosis and inflammation, indicating the progression of nonalcoholic fatty liver disease (NAFLD) (fatty liver disease associated with metabolic dysfunction) to more harmful forms of liver diseases[9]. Given this scenario, the identification of metabolic pathways that rescue gut dysbiosis and mitigate the liver changes arising from a dietary excess of saturated fat is pertinent, considering the high prevalence of obesity, its deleterious health effects, and the fact that there is, thus far, no treatment directed exclusively toward NAFLD[10].

Peroxisome proliferator-activated receptors (PPARs) are transcription factors involved in several metabolic pathways. The pharmacological activation of the PPAR-alpha isoform promotes reduced body mass, increased insulin sensitivity, the formation of beige adipocytes[11], and a significant reduction in NAFLD by increasing mitochondrial beta-oxidation[9]. Recently, PPAR-alpha deletion promoted intestinal dysbiosis and inflammation in mice[12]. The dipeptidyl-peptidase-4 (DPP-4) inhibitor linagliptin extends the glucagon-like peptide-1 (GLP1) time of action through beneficial brown and white adipocyte remodeling, browning induction, and M2 macrophage polarization, in addition to enhancing liver vascularization, supressing *de novo* lipogenesis, and alleviating endoplasmic reticulum stress[13,14].

This study aimed to address the effects of PPAR-alpha activation and DPP-4 inhibition (isolated or combined) on the gut–liver axis, emphasizing inflammatory pathways in NAFLD management in high-fat-fed C57BL/6J mice.

**MATERIALS AND METHODS**

***Animals and diet***

Adult male C57BL/6J mice were group-housed (*n* = 5 *per* cage) and maintained under controlled temperature (21 ± 2 °C) and humidity (60 ± 10%) with free access to water and feed in a ventilated rack containing cages for the mice (NexGen mouse 500, Allentown, PA, United States). The environment comprised a 12/12 h light–dark period and air renewal cycles (15 min/h). The procedures followed the recommendations of the National Institutes of Health Guide for the Care and Use of Laboratory Animals (NIH publication No. 85-23, revised 1996) and were approved by our local Ethics Committee (Institute of Biology, CEUA number 041/2018).

***Experimental protocol***

Fifty adult male C57BL/6J mice (3 month old) from the Central Biotery of the Federal Minas Gerais University were used in this study. Initially, the animals were randomly assigned to two nutritionally different groups: (1) Control group (C)–animals that received a control diet (14% of energy as protein, 10% as fat, and 76% as carbohydrates; total energy 15 KJ/g, *n* = 10); and (2) High-fat group (HF)–animals that received a high-fat diet (14% of energy as protein, 50% as fat and 36% as carbohydrates; total energy 21 KJ/g, *n* = 40).

After twelve weeks, the C group and ten animals from the HF group continued the same food scheme for an additional five weeks, whereas the remaining animals from the HF group were randomly subdivided according to the treatment into the following groups: (1) HFA received the PPAR-alpha agonist (WY14643, Sigma–Aldrich, 3.5 mg/kg body mass) incorporated into the HF diet (*n* = 10) for five weeks; (2) HFL received the DPP-4 inhibitor (linagliptin, Boehringer Ingelheim, 15 mg/kg body mass) incorporated into the HF diet (*n* = 10) for five weeks; and (3) HFC received the combination of a PPAR-alpha agonist with a DPP-4 inhibitor (at the same doses used in the groups receiving monotherapy) incorporated into the HF diet (*n* = 10) for five weeks.

The entire experimental protocol lasted for 17 wk (12 wk of obesity induction + 5 wk of treatment). The doses of WY-14643 and linagliptin were based on previous experiments conducted by our group[4,9]. PragSoluções (Jaú, São Paulo, Brazil) produced the experimental diets according to the recommendations of the American Institute of Nutrition (AIN 93M)[15]. All groups were treated following the order in which the groups were described.

***Food/energy intake and body mass***

Food intake was measured daily by subtracting the remainder of the diet verified on the following day from the amount of diet offered on the previous day. Energy intake comprised the product of the food consumption and the energy contained in 1 g of each diet (in kJ). Animal body masses were assessed on a digital scale once a week (BL-3200H, precision 0.01 g).

***Metabolic analysis***

One week before sacrifice, the animals were subjected to the oral glucose tolerance test (OGTT). Under a 6-h fast (time 0) and after 15, 30, 60, and 120 minutes of the orogastric gavage of a glucose solution (2 g/kg body mass), blood samples were obtained from the caudal vein. A manual glucometer (Accu-Chek, Roche, São Paulo, SP, Brazil) was used to measure the blood glucose levels at different times. The area under the curve (AUC) indicated the oral glucose tolerance (GraphPad Prism, version 8.3 for Windows, GraphPad Software, La Jolla, CA, United States).

***Sacrifice and ELISA***

Mice were fasted for 6 h. Under intraperitoneal anesthesia with ketamine (240 mg/kg) and xylazine (30 mg/kg), blood samples obtained by cardiac puncture were separated by centrifugation (712 ×*g*) to obtain plasma samples to perform biochemical analyses. The liver, large intestine (cecum), and small intestine (jejunum and ileum) were carefully dissected, weighed, and analyzed following the protocols for different techniques.

An ELISA was performed to measure plasma GLP1 (multispecies GLP1 ELISA Kit Cat. #EZGLP1T-36K, Millipore, Missouri, United States), and LPS (multispecies LPS ELISA Kit Cat. #SEB526Ge-96T, Cloud-Clone Corp., Katy, United States). A semiautomatic spectrophotometer and a commercial kit (K117, Bioclin, Quibasa, Belo Horizonte, MG, Brazil) were used to measure hepatic triacylglycerol (TAG) as previously described[16].

***Histology***

Liver and cecum fragments fixed in Millonig-buffered formalin (pH 7.2-7.4) were subsequently dehydrated, diaphanized, embedded in Paraplast Plus (Sigma–Aldrich, St. Louis, MO, United States) and sectioned (5 μm thick) with a microtome. Slides stained with hematoxylin and eosin (liver) or Alcian Blue (Sigma Chemical Company-pH 2.5) plus Periodic Acid-Schiff (PAS, intestine-Sigma Chemical Company) were photographed using a Leica DMRBE microscope (Wetzlar, Germany) and an Infinity Lumenera digital camera (Ottawa, ON, Canada). The images were analyzed in a blinded manner with STEPanizer ([www.stepanizer.com](http://www.stepanizer.com)) as described below:

**Hepatic stereology:** Five animals *per* group and ten images *per* animal were analyzed. The volume density of liver steatosis [Vv (liver, st)] was estimated by the point-counting technique, following the formula: Vv (liver, st) = Pp (liver, st)/PT (Pp is the number of points that reached fat droplets, and PT is the total test points). The images were analyzed with STEPanizer using a 36-point test system[17].

**Gut stereology:** The number of goblet cells *per* area [QA (goblet)] was estimated using STEPanizer. All goblet cells within the test area were counted, except those touching the forbidden lines. The result was divided by the test area measured in mm2.

***16S rDNA polymerase chain reaction amplification***

The feces found in the mouse cecum were used to extract microbial DNA using the QIAamp Fast DNA Stool Mini Kit (Qiagen, Düsseldorf, Germany) according to the manufacturer's instructions. The DNA quantity, purity, and concentration were determined using Qubit (Life Technologies, Carlsbad, California, United States) and horizontal electrophoresis (1% agarose gel). Real-time quantitative polymerase chain reaction (PCR) assays were used for the relative quantification of specific phyla of microorganisms (*Bacteroidetes, Firmicutes, Actinobacteria, Proteobacteria*) in fecal microbiota from the mouse guts by detecting 16S rRNA genes. For relative quantification, the abundances of different phyla were normalized by the ΔΔCt method relative to the total bacterial amount in the samples[18]. The indicators used are described in Table 1.

***Real-time reverse transcriptase–PCR***

Total RNA was extracted from 50 mg of the liver and 70 mg of the small intestine (jejunum and ileum) using TRIzol reagent (Invitrogen, CA, United States). Afterward, the addition of 200 μL of chloroform was followed by centrifugation (1200 *g* for 10 min at 4 °C for liver samples and 12000 *g* for 15 min at 4 °C for intestine samples). The RNA extract portion was separated, and 500 μL of isopropanol was added and allowed to stand for 10 min (liver samples) or 15 min (intestine samples) to precipitate the RNA. Then, the samples were centrifuged (1200 *g* for 10 min at 4 °C for liver samples and 12000 *g* for 10 min at 4 °C for intestine samples). The isopropanol was removed, and the formed pellet was resuspended in 500 μL of 75% ethanol for liver samples or 70% ethanol (ice-cold) for intestine samples and then centrifuged (1200 *g* for 5 min at 4 °C for liver samples and 10000 *g* for 5 min at 4 °C for intestine samples).

The ethanol was removed, and the pellet was resuspended in 20 μL (liver)/50 μL (intestine) of deionized water (Milli-Q). The samples were subjected to a dry bath (50 °C for 5 min) and quantified by using Nanovue equipment (GE Life Sciences). For RNA transcription into complementary DNA (cDNA), 1.0 μg RNA was treated with DNAse I (Invitrogen, CA, United States). First-strand cDNA synthesis was performed using Oligo (dT) primers for reverse transcriptase mRNA and Superscript III (both from Invitrogen). qPCR was performed using a CFX96 recycler (Bio–Rad, Hercules, CA, United States) and SYBR Green mix (Invitrogen, Carlsbad, CA, United States). *Beta-actin* was used to correct the expression of the target genes in liver samples, and *Gapdh* was used for intestine samples. The primer sequences used are shown in Tables 2 (liver) and 3 (intestine). All gene symbols are italicized (the first letter capitalized), and protein symbols are italicized in uppercase[19].

***Data analysis***

Sample size calculation considered that, in metabolic and molecular biology analyses, if a factor increases or decreases in five replicates, the probability of occurrence is *P* = (1/2)5 = 0.05. Therefore, a minimum of 5 replicates was adopted for the analyses[20]. The data are shown as the mean and SD. During the first 12 wk, statistical analysis comprised Student’s t test and Welch's correction. At the treatment phase, data were analyzed using Brown–Forsythe and Welch one-way ANOVA with the Dunnett T3 post hoc test[21]. A *P* < 0.05 was considered significant (GraphPad Prism version 8.3 for Windows, GraphPad Software, La Jolla, CA, United States).

**RESULTS**

***Treatment reduced body mass without altering energy intake***

The animals in the C and HF groups had equal body mass (BM) at baseline. All animals tolerated the diets and treatments well. The protocol was maintained as previously stated. In the 13th week, the HF group was overweight compared to the C group (+30%), and this characteristic persisted until the end of the experiment. Figure 1A depicts these results. Although food intake did not differ between the groups (Figure 1B), the energy intake in the HF-fed groups was higher than that in the C group (Figure 1C).

***All proposed treatments rescued glucose tolerance and increased GLP1 concentrations***

Figure 2A shows the OGTT curve, in which the HF group showed a significant increase in fasting glucose (T0) compared to the C group. This difference remained until the end of the test (T120). The C group and the treated groups exhibited rescued baseline blood glucose levels at the other evaluation times (T30, T60, and T120). On the other hand, the HF group did not reach baseline glucose levels, indicating a delay after glucose overload and implying oral glucose intolerance, as confirmed by the higher AUC for OGTT in the HF group than in the C group (+23%). In contrast, all treated groups showed lower AUCs than the HF group, indicating oral glucose intolerance alleviation.

Plasma GLP1 concentrations diminished in the HF group compared to the C group (Figure 2B). As expected, treatment with linagliptin enhanced GLP1 concentrations in the HFL group (+13%), which also occurred in the HFC group and after the single treatment with the PPAR-alpha agonist in the HFA group compared to the HF group (Figure 2C).

***Treatments recovered the microbiota composition and reversed endotoxemia in HF-fed mice***

The amplified 16S rRNA genes of cecal gut bacteria were measured at the end of the experiment to evaluate the microbiota composition. The HF group showed a *Firmicutes* phylum increase coupled with decreases in the *Proteobacteria* and *Bacteroidetes* phyla compared to the C group, as shown in Figure 3A. However, all treatments reversed these phylogenetic alterations in the treated groups. The treatments restored the amount of *Bacteroidetes* to resemble that in the C group and caused a significant decrease in *Proteobacteria*, which can play a decisive role in the beneficial effects observed due to the proposed treatments. Changes in the microbiota composition in the HF group triggered increased LPS concentrations (+10%, Figure 3B), while the HFL and HFC groups showed significantly reduced plasma LPS concentrations (-11% for HFL *vs* HF and -12% for HFC *vs* HF).

The hepatic mRNA expression of both *Lbp* (Figure 3C) and *Tlr4* (Figure 3D) genes increased in the HF group compared to the C group, while the treated groups showed significantly reduced expression.

***DPP-4 inhibitor and PPAR-alpha agonist improved the intestinal barrier structure and protection***

The HF group showed an 80% decrease in intestinal *Mucin2* gene expression compared with the C group. Conversely, the HFA, HFL, and HFC groups showed significant increases in *Mucin2* expression (+439% for HFA *vs* HF, +345% for HFL *vs* HF, and +670% for HFC *vs* HF; Figure 4A).

In agreement with the previous result, the HF group also had reduced intestinal *Occludin* (-78%) and *Zo-1* (-38%) expression compared to the C group. On the other hand, the HFA group showed a 238% increase in *Occludin* expression, whereas the HFL and HFC groups had > 500% increases in the expression of this gene (Figure 4B). Regarding *Zo-1* gene expression, all treated groups had a significant increase (+166% for HFA *vs* HF, +397% for HFL *vs* HF, and +102% for HFC *vs* HF; Figure 4C).

The high intake of saturated fat altered the histochemical pattern of the intestinal mucosal cells, as revealed by the reaction with Alcian Blue and PAS. Figure 4D shows decreased mucus in the HF group, while the treatments elicited an increase in mucus production in the apical region of the crypts, followed by an increased presence of goblet cells (mucus-producing cells). Gut stereology confirmed these observations with the results of QA (goblet), which showed a reduction in the HF group compared to the C group (-44%), while the HFA (+68%), HFL (+47%), and HFC (+56%) groups showed an increase in the number of goblet cells *per* tissue area (Figure 4E).

***DPP-4 inhibitor and PPAR-alpha activation mitigated liver steatosis***

HF-fed mice exhibited noticeable microvesicular liver steatosis, while mice in all treated groups showed liver steatosis mitigation, with the liver parenchyma resembling that in the C group (Figure 5A).

In accordance with these histological findings, Vv (liver, st) in the HF group was higher than that in the C group (+38%, Figure 5B). All treated groups showed drastic reductions in liver steatosis (-72% for HFA *vs* HF, -50% for HFL *vs* HF, and -77% for HFC *vs* HF).

Consistent with the stereological findings, hepatic TAG levels increased in the HF group (+38%). Conversely, the treated groups showed lower hepatic TAG concentrations than that in the HF group (-11% for HFA, -16% for HFL, and -13% for HFC; Figure 5C).

***DPP-4 inhibition and PPAR-alpha activation attenuated macrophage activation and reduced liver inflammation in HF-fed mice***

The HF group showed higher expression of *Cd206*, which is a specific marker of macrophages, than the C group (+103%, Figure 6A). In contrast, the treated groups showed reduced *Cd206* expression (-67% for HFA *vs* HF, -65% for HFL *vs* HF, and -74% for HFC *vs* HF).

In addition to the *Cd206* results, the HF diet significantly reduced *IL-10* expression compared to the C group (-54%), whereas the combined treatment yielded an 80% decrease in HFC *IL-10* expression compared to HF (Figure 6B). *Nlrp3* showed similar results to those of the *Cd206* gene, with higher expression in the HF group than in the C group (+128%) and reduced expression in the HFA (-72%), HFL (-88%), and HFC (-85%) groups compared to the HF group (Figure 6C).

Regarding the *IL-13* cytokine, the HF group exhibited a significant increase compared to the C group (+290%). Only the HFA and HFC treatments were able to reduce the expression of this cytokine in comparison with the HF group (-39% and -67%) (Figure 6D).

**DISCUSSION**

Excessive saturated fat intake causes overweightness, oral glucose intolerance, gut dysbiosis, and morphological and functional intestinal barrier alterations. Hence, HF animals had endotoxemia with proinflammatory signals directed toward the liver, causing substantial NAFLD. Single treatment with the PPAR-alpha agonist or DPP-4 inhibitor and the combined treatment yielded beneficial results, rescuing body mass, oral glucose tolerance, gut goblet cell numerical density *per* area, *TJ* gene expression, phylogenetic microbiota distribution, and LPS concentrations. Thus, treated animals showed liver steatosis and inflammation mitigation due to gut dysbiosis and endotoxemia control.

The chronic ingestion of a diet with a high content of saturated fats increases body mass and impairs glucose and lipid metabolism[22]. Accordingly, HF-fed mice were overweight and showed oral glucose intolerance, along with difficulty in rescuing glycemic levels during the OGTT compared to the C group. These metabolic alterations were paralleled by gut dysbiosis in the HF group, confirming that dietary patterns interfere with the gut–liver axis, favoring NAFLD pathogenesis and progression.

The integrity of the intestinal barrier structure and function relates to the gut microbiota composition. The gut microbiota comprises a great diversity of symbiotic bacteria, whereas the intestinal barrier relies on junctional proteins that make this epithelium less permeable to pathogens and toxins. In this way, both mechanisms prevent metabolic dysregulation and contribute to maintaining gut homeostasis[23-25].

Dysbiosis caused by the chronic consumption of fats is usually characterized by an increase in *Firmicutes* relative to *Bacteroidetes*, as shown by the HF group. These two phyla constitute more than 90% of the phylogenetic category currently known and characterized in the intestine of experimental models[26]. Conversely, all treated groups showed a reduction in the quantitative percentage of *Firmicutes*, especially the groups treated with the DPP-4 inhibitor and the combined therapy.

The rescuing of gut dysbiosis in the treated groups resulted in marked improvements in TJ gene expression. An HF diet also impairs the junctional components present in the intestinal epithelium, making it more permeable and consequently more susceptible to the translocation of microorganisms and toxins into systemic circulation. The increase in intestinal permeability is known as a leaky gut[25,27].

The leaky gut was rescued through enhanced expression of TJ genes in all treated groups. MUCIN2 knockout mice exhibit alterations in TJ structural proteins, in addition to mitochondrial damage and inflammation, which agrees with a leaky gut[28]. The treatments significantly augmented *Mucin2*, which is the major goblet cell gene responsible for mucin secretion, in addition to the gene expression of the TJs *Occludin* and *Zo-1*[29]. PPAR-alpha has recently been described as essential for lipid droplet formation and crypt expansion in the intestine during chronic HF diet intake[30]. Sitagliptin, as a DPP-4 inhibitor, exerted protective effects on the intestinal barrier (high *occludin* and *Zo-1* levels) by GLP-2 induction in experimental colitis[31]. Herein, the combination of these drugs resulted in the highest intestinal expression of *Mucin2* and *Occludin*, indicating that adequate function of goblet cells and well-preserved TJs may underlie the mechanisms involved in the beneficial results obtained in the HFC group.

HF diet intake also impairs the epithelium lining the intestinal mucosa. The goblet cells found in the intestinal villi and crypts are mucin producers that play a crucial role in protecting and lubricating the intestinal mucosa. The number of goblet cells indirectly reflects the ability to secrete mucus[25]. Herein, the HF diet caused a reduced number of goblet cells *per* area of the gut crypt, while all treatments reversed this alteration with the normalization of the numerical density of goblet cells and *Mucin2* gene expression. Hence, the treatments supported intestinal barrier integrity and reduced the translocation of endotoxins, such as LPS, into systemic circulation, rescuing the mice from a condition called metabolic endotoxemia[32].

The high translocation of endotoxins derived from the gut microbiota induces Toll-like receptor (TLR) activation. LPS is the most common pathogen-associated molecular pattern (PAMP), and its binding to TLR4 is catalyzed by lipopolysaccharide-binding protein (LBP), which is mainly expressed in the liver and adipose tissue[32].

LPS stems from the destruction of the bacterial cell wall. An increase in LPS in systemic circulation triggers the release of proinflammatory cytokines and an inadequate amplification of the immune response, causing tissue damage[26]. An increase in plasma LPS levels was observed in the HF group, characterizing the involvement of the epithelium with a consequent increase in intestinal permeability, making the epithelium more permeable to the entry of microorganisms. Additionally, we showed that hepatic *Lbp* and *Tlr4* gene expression increased in the HF group, inducing the translocation of cytokines associated with inflammation and changing hepatic lipid metabolism, reconfiguring this metabolism to become a potent inducer of fatty liver, and contributing to the pathogenesis of NAFLD.

In contrast, the treatments normalized *Lbp* and *Tlr4* expression, with both emerging as targets for NAFLD treatment. The DPP-4 inhibitor alogliptin suppressed TLR4 *via* ERK activation, resulting in decreased matrix metalloproteinases and proinflammatory cytokines in U937 histiocytes[33]. Sitagliptin was previously shown to attenuate NAFLD by suppressing inflammation and insulin resistance due to TLR4/NF-kB pathway downregulation in diabetic rats[34]. PPAR-alpha activation by WY-14643 mitigated liver steatosis in high-fructose-fed mice by reducing LPS concentrations, improving the intestinal barrier ultrastructure, upregulating hepatic beta-oxidation, and suppressing lipogenesis in mice[9].

A recent study showed that systemic LBP blockade or decreased LBP levels in the liver normalized glucose homeostasis, mainly by reducing fasting glucose levels, without changing adiposity or liver steatosis[35]. In this study, the group treated with the PPAR-alpha agonist as monotherapy did not show reduced LPS concentrations. However, the treatment reduced *Lbp* expression, producing anti-inflammatory and anti-steatotic effects similar to those of the other treatments.

In this context, macrophages play roles in acute and chronic inflammatory liver diseases. Macrophages have receptors, such as CD163 and CD206, which participate in the phagocytosis of harmful substances. Due to its high affinity for macrophages, CD206 is a potential biomarker of hepatic macrophage (Kupffer cells) activation, which indicates inflammation and fibrosis in chronic liver diseases[36]. In response to LPS and other stimuli, the metabolic profile of macrophages and dendritic cells stimulates the glycolytic pathway, resulting in the metabolic accumulation of citrate and succinate, which, in turn, regulate the gene expression of cytokines such as interleukin 10 (IL-10)[37]. Recent evidence shows that IL-10 may play a dual role in some contexts by stimulating the immune response rather than suppressing it. However, the cytokine IL-10 has emerged as an anti-inflammatory mediator determining the protection of its host in response to pathogens[38].

Our results showed that *Cd206* macrophages were activated in the HF group, reinforcing the idea that the chronic consumption of this type of diet activates inflammatory pathways that contribute to the development of liver disease. In contrast, the groups treated with the PPAR-alpha activator and DPP-4 inhibitor showed reduced expression of *Cd206* macrophages, conferring a protective effect against the activation of inflammatory pathways. Recent evidence showed that highly fibrous livers had a higher density of *Cd206* macrophages[36]. *IL-10* gene expression was reduced in the HF group. However, only the combined treatment increased *IL-10* expression, implying that the isolated treatments might have acted through another anti-inflammatory pathway. IL-13 overexpression in HF diet-fed mice is a pathway related to fatty liver and insulin resistance onset. Combined treatment and PPAR-alpha activation alone markedly reduced hepatic *IL-13* expression, which combined with reduced macrophage activation and glycemic homeostasis to alleviate fatty liver[39].

Concerning inflammasomes, NLRP3 is present mainly in immune and inflammatory cells, such as macrophages, monocytes, dendritic cells, and neutrophils, after activation by inflammatory stimuli. NLRP3 is activated by numerous PAMPs, such as hyperglycemia, fatty acids, bacterial toxins, and bacterial and viral nucleic acids[40]. Studies in macrophages and animal models have shown that oxidized low-density lipoproteins and cholesterol crystals trigger NLRP3 activation. In macrophage and type 2 diabetes animal models, glucose and free fatty acids trigger inflammasome activation, damaging glucose metabolism and favoring insulin resistance[41]. Thus, NLRP3 may contribute to the appearance and progression of several diseases related to metabolic syndrome.

In this study, we showed that treatment with the PPAR-alpha agonist and DPP-4 inhibitor produced a potent anti-inflammatory effect in the liver, as they demonstrated reduced gene expression of *Nlrp3* and *Cd206*. The blockade of NLRP3 has recently improved NAFLD and mitigated liver fibrosis in two models of steatohepatitis[42], highlighting the proposed treatments as viable tools to control fatty liver. Two DPP-4 inhibitors were previously shown to suppress NLRP3 in human macrophages by downregulating the TLR4-IL-1beta pathway[43]. Sitagliptin alleviated liver injury caused by thioacetamide in mice by decreasing NLRP3 and exerting anti-apoptotic effects[44]. Regarding PPAR-alpha activation, oleoylethanolamide protected against LPS-induced liver injury in mice by suppressing NLRP3[45]. However, the present study is the first to report the effects of both drugs and their combination on the gut–liver axis in HF-fed mice. Figure 7 summarizes our main findings.

Some limitations of the present study comprise the absence of female mice evaluations to determine possible sexual dimorphism, the lack of plasma glucose concentration measurements, and the inability to determine LBP concentrations, although its gene expression was evaluated. Future research should also include the evaluation of genera and families in the *Proteobacteria* phylum, as it seems to be involved in the harmful evolution of NAFLD.

**CONCLUSION**

In conclusion, HF-fed mice showed impairment of the intestinal barrier and alteration in the phylogenetic diversity of the gut microbiota, leading to dysbiosis, and contributing to the influx of LPS into the liver. An impaired gut–liver axis favors liver damage, making the liver more susceptible to NAFLD through proinflammatory signals (*Tlr4* and *Nlrp3* upregulation). Treatment with the PPAR-alpha agonist and the DPP-4 inhibitor modulated the gut microbiota and rescued intestinal barrier gene expression and goblet cell numerical density, reducing endotoxemia and liver steatosis through anti-inflammatory signaling. Given the beneficial effects of the treatments found, these treatments have become possible therapeutic strategies for the NAFLD spectrum of diseases.

**ARTICLE HIGHLIGHTS**

***Research background***

Gut microbiota can be modified by the dietary composition and play a role in fatty liver pathogenesis through endotoxemia. Peroxisome proliferator-activated receptor (PPAR)-alpha activation has previously rescued the gut–liver axis with anti-steatotic effects in high-fructose-fed mice, whereas a high-dose dipeptidyl peptidase-4 (DPP-4) inhibitor (linagliptin) inhibited hepatic lipogenesis in high-fat-fed mice. The combination of these drugs could restore the gut–liver axis in obese mice.

***Research motivation***

Nonalcoholic fatty liver disease (NAFLD) is highly prevalent among obese individuals and can evolve into harmful liver diseases. Currently, there is no treatment directly prescribed to counter NAFLD. Herein, we propose a drug combination (PPAR-alpha agonist plus DPP-4 inhibitor) that can alleviate fatty liver by modulating the gut–liver axis with anti-inflammatory properties.

***Research objectives***

To evaluate the effects of monotherapy with a PPAR-alpha agonist (WY14643) or a DPP-4 inhibitor (linagliptin) and their combined treatment on the gut–liver axis, highlighting the intestinal barrier, endotoxemia, and inflammatory pathways in the livers of high-fat-fed mice. These preclinical insights can help establish new strategies for the treatment of NAFLD.

***Research methods***

Mice were fed a control diet (C, 10% of energy as lipids) or a high-fat diet (HF, 50% of energy as lipids) for 12 wk. Then, the HF group was randomly divided into four groups: HF, HF-A (treated with the PPAR-alpha agonist), HFL (treated with the DPP-4 inhibitor), and HFC (treated with the combination of both drugs). The treatments lasted for five weeks. The gut–liver axis was assessed by histological, biochemical, stereological, and molecular techniques.

***Research results***

The HF diet yielded overweightness and oral glucose intolerance, altered gut microbiota composition, and decreased the numerical density of goblet cells and tight junction gene expression, with increased plasma lipopolysaccharide (LPS) concentrations and increased fatty liver. The combined treatment rescued all of these metabolic alterations by restoring the gut microbiota and intestinal barrier markers, resulting in decreased LPS concentrations and fatty liver through anti-inflammatory signals. Further studies may focus on the *Proteobacteria* phylum, whose alteration can trigger harmful signaling to the liver.

***Research conclusions***

The combination of PPAR-alpha activation with DPP-4 inhibition yielded marked anti-steatotic effects by modulating the gut–liver axis, with reduced endotoxemia and amelioration of the intestinal barrier histology and gene expression. In turn, the livers of obese mice treated with the drug combination benefited from downregulation of the *Tlr4* and *Nlrp3* pathways and exhibited a hepatic parenchyma similar to that in the C group. Of note, we used stereology to estimate the numerical density of goblet cells in cecum slides stained with Alcian Blue and Periodic Acid-Schiff. This technique can be used to assess the effects of different interventions on the intestinal barrier and leaky gut in further studies.

***Research perspectives***

This study brings novelty to the treatment of NAFLD, which is a challenge to the scientific community. Our results confirm the importance of the gut–liver axis in the pathogenesis of fatty liver and propose a combined treatment that targets the gut microbiota composition, endotoxemia, and intestinal barrier alterations to alleviate fatty liver through local anti-inflammatory effects in HF-fed mice.

**ACKNOWLEDGEMENTS**

The authors would like to thank Aline Penna for her technical assistance.

**REFERENCES**

1 **GBD 2017 Diet Collaborators**. Health effects of dietary risks in 195 countries, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet* 2019; **393**: 1958-1972 [PMID: 30954305 DOI: 10.1016/S0140-6736(19)30041-8]

2 **Hruby A**, Hu FB. The Epidemiology of Obesity: A Big Picture. *Pharmacoeconomics* 2015; **33**: 673-689 [PMID: 25471927 DOI: 10.1007/s40273-014-0243-x]

3 **Volynets V**, Louis S, Pretz D, Lang L, Ostaff MJ, Wehkamp J, Bischoff SC. Intestinal Barrier Function and the Gut Microbiome Are Differentially Affected in Mice Fed a Western-Style Diet or Drinking Water Supplemented with Fructose. *J Nutr* 2017; **147**: 770-780 [PMID: 28356436 DOI: 10.3945/jn.116.242859]

4 **Miranda CS**, Silva-Veiga F, Martins FF, Rachid TL, Mandarim-De-Lacerda CA, Souza-Mello V. PPAR-α activation counters brown adipose tissue whitening: a comparative study between high-fat- and high-fructose-fed mice. *Nutrition* 2020; **78**: 110791 [PMID: 32682271 DOI: 10.1016/j.nut.2020.110791]

5 **Matsushita N**, Osaka T, Haruta I, Ueshiba H, Yanagisawa N, Omori-Miyake M, Hashimoto E, Shibata N, Tokushige K, Saito K, Tsuneda S, Yagi J. Effect of Lipopolysaccharide on the Progression of Non-Alcoholic Fatty Liver Disease in High Caloric Diet-Fed Mice. *Scand J Immunol* 2016; **83**: 109-118 [PMID: 26524607 DOI: 10.1111/sji.12397]

6 **Leung C**, Rivera L, Furness JB, Angus PW. The role of the gut microbiota in NAFLD. *Nat Rev Gastroenterol Hepatol* 2016; **13**: 412-425 [PMID: 27273168 DOI: 10.1038/nrgastro.2016.85]

7 **Zhou X**, Han D, Xu R, Li S, Wu H, Qu C, Wang F, Wang X, Zhao Y. A model of metabolic syndrome and related diseases with intestinal endotoxemia in rats fed a high fat and high sucrose diet. *PLoS One* 2014; **9**: e115148 [PMID: 25502558 DOI: 10.1371/journal.pone.0115148]

8 **Gray H**. Gray Anatomia Charles Mayo Goss. Rio de Janeiro: Guanabara Koogan; 1988

9 **Silva-Veiga FM**, Miranda CS, Martins FF, Daleprane JB, Mandarim-de-Lacerda CA, Souza-Mello V. Gut-liver axis modulation in fructose-fed mice: a role for PPAR-alpha and linagliptin. *J Endocrinol* 2020; **247**: 11-24 [PMID: 32698143 DOI: 10.1530/JOE-20-0139]

10 **Younossi ZM**, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. *Hepatology* 2016; **64**: 73-84 [PMID: 26707365 DOI: 10.1002/hep.28431]

11 **Rachid TL**, Silva-Veiga FM, Graus-Nunes F, Bringhenti I, Mandarim-de-Lacerda CA, Souza-Mello V. Differential actions of PPAR-α and PPAR-β/δ on beige adipocyte formation: A study in the subcutaneous white adipose tissue of obese male mice. *PLoS One* 2018; **13**: e0191365 [PMID: 29351550 DOI: 10.1371/journal.pone.0191365]

12 **Manoharan I**, Suryawanshi A, Hong Y, Ranganathan P, Shanmugam A, Ahmad S, Swafford D, Manicassamy B, Ramesh G, Koni PA, Thangaraju M, Manicassamy S. Homeostatic PPARα Signaling Limits Inflammatory Responses to Commensal Microbiota in the Intestine. *J Immunol* 2016; **196**: 4739-4749 [PMID: 27183583 DOI: 10.4049/jimmunol.1501489]

13 **Santana-Oliveira DA**, Fernandes-da-Silva A, Miranda CS, Martins FF, Mandarim-de-Lacerda CA, Souza-Mello V. A PPAR-alpha agonist and DPP-4 inhibitor mitigate adipocyte dysfunction in obese mice. *J Mol Endocrinol* 2022 [PMID: 35302950 DOI: 10.1530/JME-21-0084]

14 **Sakai Y**, Chen G, Ni Y, Zhuge F, Xu L, Nagata N, Kaneko S, Ota T, Nagashimada M. DPP-4 Inhibition with Anagliptin Reduces Lipotoxicity-Induced Insulin Resistance and Steatohepatitis in Male Mice. *Endocrinology* 2020; **161** [PMID: 32790863 DOI: 10.1210/endocr/bqaa139]

15 **Reeves PG**, Nielsen FH, Fahey GC Jr. AIN-93 purified diets for laboratory rodents: final report of the American Institute of Nutrition ad hoc writing committee on the reformulation of the AIN-76A rodent diet. *J Nutr* 1993; **123**: 1939-1951 [PMID: 8229312 DOI: 10.1093/jn/123.11.1939]

16 **Catta-Preta M**, Mendonca LS, Fraulob-Aquino J, Aguila MB, Mandarim-de-Lacerda CA. A critical analysis of three quantitative methods of assessment of hepatic steatosis in liver biopsies. *Virchows Arch* 2011; **459**: 477-485 [PMID: 21901430 DOI: 10.1007/s00428-011-1147-1]

17 **Tschanz SA**, Burri PH, Weibel ER. A simple tool for stereological assessment of digital images: the STEPanizer. *J Microsc* 2011; **243**: 47-59 [PMID: 21375529 DOI: 10.1111/j.1365-2818.2010.03481.x]

18 **Livak KJ**, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. *Methods* 2001; **25**: 402-408 [PMID: 11846609 DOI: 10.1006/meth.2001.1262]

19 **Davisson MT**. Rules and guidelines for nomenclature of mouse genes. International Committee on Standardized Genetic Nomenclature for Mice. *Gene* 1994; **147**: 157-160 [PMID: 7926794 DOI: 10.1016/0378-1119(94)90060-4]

20 **Cruz-Orive LM**, Weibel ER. Recent stereological methods for cell biology: a brief survey. *Am J Physiol* 1990; **258**: L148-L156 [PMID: 2185653 DOI: 10.1152/ajplung.1990.258.4.L148]

21 **Dunnett CW**. Pairwise multiple comparisons in the unequal variance case. *J Am Stat Assoc* 1980; **75:** 796-800 [DOI: 10.1080/01621459.1980.10477552]

22 **De Lorenzo A**, Gratteri S, Gualtieri P, Cammarano A, Bertucci P, Di Renzo L. Why primary obesity is a disease? *J Transl Med* 2019; **17**: 169 [PMID: 31118060 DOI: 10.1186/s12967-019-1919-y]

23 **Cremonini E**, Daveri E, Mastaloudis A, Adamo AM, Mills D, Kalanetra K, Hester SN, Wood SM, Fraga CG, Oteiza PI. Anthocyanins protect the gastrointestinal tract from high fat diet-induced alterations in redox signaling, barrier integrity and dysbiosis. *Redox Biol* 2019; **26**: 101269 [PMID: 31330482 DOI: 10.1016/j.redox.2019.101269]

24 **Blüher M**. Obesity: global epidemiology and pathogenesis. *Nat Rev Endocrinol* 2019; **15**: 288-298 [PMID: 30814686 DOI: 10.1038/s41574-019-0176-8]

25 **Odenwald MA**, Turner JR. The intestinal epithelial barrier: a therapeutic target? *Nat Rev Gastroenterol Hepatol* 2017; **14**: 9-21 [PMID: 27848962 DOI: 10.1038/nrgastro.2016.169]

26 **Schoeler M**, Caesar R. Dietary lipids, gut microbiota and lipid metabolism. *Rev Endocr Metab Disord* 2019; **20**: 461-472 [PMID: 31707624 DOI: 10.1007/s11154-019-09512-0]

27 **Ortigão R**, Pimentel-Nunes P, Dinis-Ribeiro M, Libânio D. Gastrointestinal Microbiome - What We Need to Know in Clinical Practice. *GE Port J Gastroenterol* 2020; **27**: 336-351 [PMID: 32999906 DOI: 10.1159/000505036]

28 **Borisova MA**, Achasova KM, Morozova KN, Andreyeva EN, Litvinova EA, Ogienko AA, Morozova MV, Berkaeva MB, Kiseleva E, Kozhevnikova EN. Mucin-2 knockout is a model of intercellular junction defects, mitochondrial damage and ATP depletion in the intestinal epithelium. *Sci Rep* 2020; **10**: 21135 [PMID: 33273633 DOI: 10.1038/s41598-020-78141-4]

29 **Meyer R**. Comment on Guenette, S.A., Beaudry, F., Marier, J.F., and Vachon, P. (2006). Pharmacokinetics and anesthetic activity of eugenol in male Sprague-Dawley rats. J. Vet. Pharmacol. Ther. 29, 265-270. *J Vet Pharmacol Ther* 2007; **30**: 91; author reply 92 [PMID: 17217408 DOI: 10.1111/j.1365-2885.2007.00814.x]

30 **Stojanović O**, Altirriba J, Rigo D, Spiljar M, Evrard E, Roska B, Fabbiano S, Zamboni N, Maechler P, Rohner-Jeanrenaud F, Trajkovski M. Dietary excess regulates absorption and surface of gut epithelium through intestinal PPARα. *Nat Commun* 2021; **12**: 7031 [PMID: 34857752 DOI: 10.1038/s41467-021-27133-7]

31 **Ning MM**, Yang WJ, Guan WB, Gu YP, Feng Y, Leng Y. Dipeptidyl peptidase 4 inhibitor sitagliptin protected against dextran sulfate sodium-induced experimental colitis by potentiating the action of GLP-2. *Acta Pharmacol Sin* 2020; **41**: 1446-1456 [PMID: 32398684 DOI: 10.1038/s41401-020-0413-7]

32 **Do MH**, Lee E, Oh MJ, Kim Y, Park HY. High-Glucose or -Fructose Diet Cause Changes of the Gut Microbiota and Metabolic Disorders in Mice without Body Weight Change. *Nutrients* 2018; **10** [PMID: 29899272 DOI: 10.3390/nu10060761]

33 **Ta NN**, Li Y, Schuyler CA, Lopes-Virella MF, Huang Y. DPP-4 (CD26) inhibitor alogliptin inhibits TLR4-mediated ERK activation and ERK-dependent MMP-1 expression by U937 histiocytes. *Atherosclerosis* 2010; **213**: 429-435 [PMID: 20843518 DOI: 10.1016/j.atherosclerosis.2010.08.064]

34 **Allam MM**, Ibrahim RM, El Gazzar WB, Said MA. Dipeptedyl peptidase-4 (DPP-4) inhibitor downregulates HMGB1/TLR4/NF-κB signaling pathway in a diabetic rat model of non-alcoholic fatty liver disease. *Arch Physiol Biochem* 2021: 1-9 [PMID: 34543583 DOI: 10.1080/13813455.2021.1975758]

35 **Molinaro E**, Andrikou K, Casadei-Gardini A, Rovesti G. BRCA in Gastrointestinal Cancers: Current Treatments and Future Perspectives. *Cancers (Basel)* 2020; **12** [PMID: 33198203 DOI: 10.3390/cancers12113346]

36 **Nielsen MC**, Hvidbjerg Gantzel R, Clària J, Trebicka J, Møller HJ, Grønbæk H. Macrophage Activation Markers, CD163 and CD206, in Acute-on-Chronic Liver Failure. *Cells* 2020; **9** [PMID: 32397365 DOI: 10.3390/cells9051175]

37 **Kelly B**, O'Neill LA. Metabolic reprogramming in macrophages and dendritic cells in innate immunity. *Cell Res* 2015; **25**: 771-784 [PMID: 26045163 DOI: 10.1038/cr.2015.68]

38 **Saraiva M**, Vieira P, O'Garra A. Biology and therapeutic potential of interleukin-10. *J Exp Med* 2020; **217** [PMID: 31611251 DOI: 10.1084/jem.20190418]

39 **Darkhal P**, Gao M, Ma Y, Liu D. Blocking high-fat diet-induced obesity, insulin resistance and fatty liver by overexpression of Il-13 gene in mice. *Int J Obes (Lond)* 2015; **39**: 1292-1299 [PMID: 25869601 DOI: 10.1038/ijo.2015.52]

40 **Groslambert M**, Py BF. Spotlight on the NLRP3 inflammasome pathway. *J Inflamm Res* 2018; **11**: 359-374 [PMID: 30288079 DOI: 10.2147/JIR.S141220]

41 **Duewell P**, Kono H, Rayner KJ, Sirois CM, Vladimer G, Bauernfeind FG, Abela GS, Franchi L, Nuñez G, Schnurr M, Espevik T, Lien E, Fitzgerald KA, Rock KL, Moore KJ, Wright SD, Hornung V, Latz E. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. *Nature* 2010; **464**: 1357-1361 [PMID: 20428172 DOI: 10.1038/nature08938]

42 **Mridha AR**, Wree A, Robertson AAB, Yeh MM, Johnson CD, Van Rooyen DM, Haczeyni F, Teoh NC, Savard C, Ioannou GN, Masters SL, Schroder K, Cooper MA, Feldstein AE, Farrell GC. NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice. *J Hepatol* 2017; **66**: 1037-1046 [PMID: 28167322 DOI: 10.1016/j.jhep.2017.01.022]

43 **Dai Y**, Dai D, Wang X, Ding Z, Mehta JL. DPP-4 inhibitors repress NLRP3 inflammasome and interleukin-1beta *via* GLP-1 receptor in macrophages through protein kinase C pathway. *Cardiovasc Drugs Ther* 2014; **28**: 425-432 [PMID: 25022544 DOI: 10.1007/s10557-014-6539-4]

44 **El-Kashef DH**, Serrya MS. Sitagliptin ameliorates thioacetamide-induced acute liver injury *via* modulating TLR4/NF-KB signaling pathway in mice. *Life Sci* 2019; **228**: 266-273 [PMID: 31077717 DOI: 10.1016/j.lfs.2019.05.019]

45 **Hu J**, Zhu Z, Ying H, Yao J, Ma H, Li L, Zhao Y. Oleoylethanolamide Protects Against Acute Liver Injury by Regulating Nrf-2/HO-1 and NLRP3 Pathways in Mice. *Front Pharmacol* 2020; **11**: 605065 [PMID: 33536915 DOI: 10.3389/fphar.2020.605065]

**Footnotes**

**Institutional review board statement:** The study was reviewed and approved by the CEUA of State University of Rio de Janeiro Institutional Review Board, No. 041/2018.

**Conflict-of-interest statement:** The authors have no conflict of interest to declare.

**Data sharing statement:** Technical appendix, statistical code, and dataset available from the corresponding author at souzamello.uerj@gmail.com.

**ARRIVE guidelines statement:** The authors have read the ARRIVE Guidelines, and the manuscript was prepared and revised according to the ARRIVE Guidelines.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Invited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review started:** December 30, 2021

**First decision:** January 27, 2022

**Article in press:**

**Specialty type:** Gastroenterology and hepatology

**Country/Territory of origin:** Brazil

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B, B


Grade C (Good): 0

Grade D (Fair): 0


Grade E (Poor): 0

**P-Reviewer:** Dziegielewska-Gesiak S, Poland; Li YL, China **S-Editor:** Fan JR **L-Editor:** A **P-Editor:** Fan JR


**Figure Legends**




**Figure 1 Body mass and food behavior.** A: Body mass evolution; B: Food intake; C: Energy intake. Brown-Forsythe and Welch one-way ANOVA and Dunnett T3 *post hoc* test (mean ± SD, *n* = 6). Significant differences are indicated as follows: a*P* < 0.05; b*P* < 0.01; d*P* < 0.0001. C: Control diet; HF: High-fat diet; HFA: High-fat diet plus PPAR-alpha agonist (WY14643); HFL: High-fat diet plus DPP-4 inhibitor (linagliptin); HFC: High-fat diet plus the combination of WY14643 with linagliptin.




**Figure 2 Carbohydrate metabolism.** A: Oral glucose tolerance test; B: Area under the curve for oral glucose tolerance test; C: Plasma glucagon-like peptide 1 concentrations. Brown-Forsythe and Welch one-way ANOVA and Dunnett T3 *post hoc* test (mean ± SD, *n* = 6). Significant differences are indicated as follows: a*P* < 0.05; c*P* < 0.001; d*P* < 0.0001. C: Control diet; HF: High-fat diet; HFA: High-fat diet plus PPAR-alpha agonist (WY14643); HFL: High-fat diet plus DPP-4 inhibitor (linagliptin); HFC: High-fat diet plus the combination of WY14643 with linagliptin; AUC: Area under the curve; OGTT: Oral glucose tolerance test; GLP1: Glucagon-like peptide 1.




**Figure 3 Gut-liver axis.** A: Phylogenetic microbiota composition; B: Plasma lipopolysaccharide concentrations; C: Hepatic *Lbp* gene expression; D: Hepatic *Tlr4* gene expression. Brown-Forsythe and Welch one-way ANOVA and Dunnett T3 *post hoc* test (mean ± SD, *n* = 6). Significant differences are indicated as follows: a*P* < 0.05; b*P* < 0.01; c*P* < 0.001; d*P* < 0.0001. C: Control diet; HF: High-fat diet; HFA: High-fat diet plus PPAR-alpha agonist (WY14643); HFL: High-fat diet plus DPP-4 inhibitor (linagliptin); HFC: High-fat diet plus the combination of WY14643 with linagliptin; LPS: Lipopolysaccharide.




**Figure 4 Gut gene expression, histology, and stereology.** A: Gut *Mucin2*; B: *Zo-1*; C: *Occludin* gene expression; D: Large intestine stained with Alcian Blue and Periodic Acid-Schiff (PAS); E: Numerical density of goblet cells *per* area. Alcian blue and PAS stain glycoproteins produced by goblet cells (scale bar = 40 μm), which were markedly reduced by the high-fat diet and rescued by the treatments according to stereology (QA goblet). Brown-Forsythe and Welch one-way ANOVA and Dunnett T3 *post hoc* test (mean ± SD, *n* = 6 for real-time reverse transcriptase–polymerase chain reaction and *n* = 5 for stereology). Significant differences are indicated as follows: a*P* < 0.05; b*P* < 0.01; c*P* < 0.001; d*P* < 0.0001. C: Control diet; HF: High-fat diet; HFA: High-fat diet plus PPAR-alpha agonist (WY14643); HFL: High-fat diet plus DPP-4 inhibitor (linagliptin); HFC: High-fat diet plus the combination of WY14643 with linagliptin; PAS: Periodic Acid-Schiff; QA: Numerical density *per* area.



**Figure 5 Liver histology, stereology, and biochemistry.** A: Hematoxylin-eosin liver sections; B: Volume density (Vv) (liver steatosis); C: Hepatic triacylglycerol. Liver sections show widespread hepatic steatosis after chronic HF diet intake and expressive reduction in all treated groups (scale bar = 50 μm. Both stereology (Vv steatosis) and biochemical analyses (hepatic triacylglycerol) confirm these observations. Brown-Forsythe and Welch one-way ANOVA and Dunnett T3 *post hoc* test (mean ± SD, *n* = 6 for biochemistry and *n* = 5 for stereology). Significant differences are indicated as follows: a*P* < 0.05; b*P* < 0.01; c*P* < 0.001; d*P* < 0.0001. C: Control diet; HF: High-fat diet; HFA: High-fat diet plus PPAR-alpha agonist (WY14643); HFL: High-fat diet plus DPP-4 inhibitor (linagliptin); HFC: High-fat diet plus the combination of WY14643 with linagliptin; Vv: Volume density.



**Figure 6 Liver gene expression.** A: *Cd206*; B: *IL-10*; C: *Nlrp3*; D: *IL-13*. Brown-Forsythe and Welch one-way ANOVA and Dunnett T3 *post hoc* test (mean ± SD, *n* = 5 or 6). Significant differences are indicated as follows: a*P* < 0.05; b*P* < 0.01; c*P* < 0.001; d*P* < 0.0001. C: Control diet; HF: High-fat diet; HFA: High-fat diet plus PPAR-alpha agonist (WY14643); HFL: High-fat diet plus DPP-4 inhibitor (linagliptin); HFC: High-fat diet plus the combination of WY14643 with linagliptin.



**Figure 7 Main findings of the study.** All treatments alleviated fatty liver by countering gut dysbiosis and rescuing the intestinal barrier integrity. The reduced lipopolysaccharide (LPS) influx to the liver caused reduced inflammasome and CD206 macrophage activation. Peroxisome proliferator-activated receptor-alpha activation and DPP-4 inhibition can be regarded as viable tools to treat leaky gut and prevent LPS-driven hepatic steatosis. PPAR: Peroxisome proliferator-activated receptor; DPP-4: Dipeptidyl peptidase-4; LPS: Lipopolysaccharide; LBP: Lipopolysaccharide-binding protein; TLR4: Toll-Like receptor 4; ZO-1: Zonula occludens 1; NLRP3: NLR family pyrin domain containing 3; CD206: Cluster of differentiation 206; IL: Interleukin. Created with Biorender: [www.biorender.com](file:///C:\\Users\\Administrator\\AppData\\Local\\Temp\\Rar$DIa6628.49289\\www.biorender.com).

**Table 1 Initiators of the phylum or class of microorganisms of gut microbiota**

|  |  |  |
| --- | --- | --- |
| **Phylum or class** | **Forward initiator** | **Reverse initiator** |
| *Eubacteria (All Bacteria)* | [5’-ACTCCTACGGGAGGCAGAGT-3’] | [5’-ATTACCGCGGCTGCTGGC-3’] |
| *Bacteroidetes* | [5’-CRAACAGGATTAGATACCCT-3’] | [5’-GGTAAGGTTCCTCGCGTAT-3’] |
| *Firmicutes* | [5’-TGAAACTYAAAGGAATTGACG-3’] | [5’-ACCATGCACCACCTGTC-3’] |
| *Actinobacteria* | [5’-TACGGCCGCAAGGCTA-3’] | [5’-TCRTCCCCACCTTCCTCCG-3’] |
| *Class-γ-Proteobacteria* | [5’-TCGTCAGCTCGTGTYGTGA -3’] | [5’-CGTAAGGGCCATGATG-3’] |

**Table 2 Forward and reverse sequences of real-time reverse transcriptase–polymerase chain reaction primers–liver**

|  |  |  |
| --- | --- | --- |
| **Gene** | **5’-3’ Left** | **3’-5’ Right** |
| *Lbp* | GGTGGCTGCTGAATCTCTTC | TCTGCTGTGACTGGCAGAGT |
| *Tlr4* | GCCGGAAGGTTATTGTGGTA | GAAACTGCCATGTTTGAGCA |
| *Nlrp3* | ATGCTGCTTCGACATCTCCT | GTTTCTGGAGGTTGCAGAGC |
| *Cd206* | CAAGGAAGGTTGGCATTTGT | CCTTTCAGTCCTTTGCAAGC |
| *IL-10* | GCCTTATCGGAAATGATCCA | TCCTGAGGGTCTTCAGCTTC |
| *IL-13* | CTGGATTCCCTGACCAACAT | GGTTACAGAGGCCATGCAAT |
| *Beta-actin* | TGTTACCAACTGGGACGACA | GGGGTGTTGAAGGTCTCAAA |

**Table 3 Forward and reverse sequences of real-time reverse transcriptase–polymerase chain reaction primers–intestine**

|  |  |  |
| --- | --- | --- |
| **Gene** | **5’-3’ Left** | **3’-5’ Right** |
| *Mucin2* | GTAGTTTCCGTTGGAACAGTGAA | ATGCCCACCTCCTCAAAGAC |
| *Occludin* | CCTTCTGCTTCATCGCTTCC | AGCGCTGACTATGATCACGA |
| *Zo-1* | TCAGAGCCCTCCGATCATTC | GCTTTGGGTGGATGATCGTC |
| *Tlr4* | GCCGGAAGGTTATTGTGGTA | GAAACTGCCATGTTTGAGCA |
| *Gapdh* | CATCACTGCCACCCAGAAGACTG | ATGCCAGTGAGCTTCCCGTTCAG |